Bim Expression Could Predict Patient Response to PD-1 Blockade, Mayo Clinic Study Finds
Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.
A new study by researchers at the Mayo Clinic, presented at the American Association for Cancer Research International Cancer Immunotherapy Conference,
Despite promising results, immuno-oncology agents, particularly the PD-1 and PD-L1 agents, have not had much success with a predictive biomarker. Results have actually been mixed with correlating PD-L1 expression with treatment response. One study,
The current study evaluated response in 38 metastatic melanoma patients being treated with pembrolizumab by drawing a series of blood samples that were then assayed by flow cytometry. Blood samples were collected and every 3 months after treatment. Patients with high levels of Bim expression on their T-cells responded to treatment while those who had relatively lower expression of the protein did not respond, as measured by RECIST 1.1 complete response, partial response, or stable disease after 4 cycles of treatment. Responders also had increased expression of soluble PD-L1 in their blood prior to treatment.
“The discovery of biomarkers of sensitivity are vital not only for informing clinical decisions, but also to help identify which patients with melanoma, and possibly other malignancies, who are most likely to benefit from PD-1 blockade,” says Roxana Dronca, MD, a hematologist at Mayo Clinic and lead author of the abstract. “This will allow us to expose fewer patients to inadequate treatments, and their associated toxicities and costs.”
A major advantage of the method used is the use of circulating peripheral blood cells, which will avoid repeated tissue biopsies for the patient.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Modest Reductions in PrEP Coverage Result in Avoidable HIV Infections
September 17th 2025